The panel discuss the key points that emerged from the second day of the 10^th iwNHL meeting in Boston. The topics discussed include T-cell-mediated immunotherapy with a chimeric antigen receptor (CAR), the identification of defects in epigenetic pathways associated with follicular lymphoma, the potential benefits of lenalidomide to different lymphoma sub-types and probable beneficial and adverse effects of drugs that target NF-κB.

In addition, the panel address concerns regarding the regulation of bio-similar versions of biological agents, discuss the toxicities associated with immunotherapies, including the potential long term reduction of patient B-cell levels, outline the potential costs and benefits of chronic treatment with ECR receptor signalling drugs and explain the approaches taken to reduce toxicities of the BiTE monoclonal antibody blinatumomab.